Immune signature as predictive marker for response to checkpoint inhibitor immunotherapy and overall survival in melanoma

BACKGROUND: Malignant melanoma is an immunogenic skin cancer with an increasing global incidence. Advanced stages of melanoma have poor prognoses. Currently, there are no reliable parameters to predict a patient's response to immune checkpoint inhibitor (ICI) therapy. METHODS: This study highli...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Cancer Med
Hlavní autoři: Krebs, Franziska K., Trzeciak, Emily R., Zimmer, Sophia, Özistanbullu, Deniz, Mitzel‐Rink, Heidrun, Meissner, Markus, Grabbe, Stephan, Loquai, Carmen, Tuettenberg, Andrea
Médium: Artigo
Jazyk:Inglês
Vydáno: John Wiley and Sons Inc. 2021
Témata:
Clinical Cancer Research
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC7940230/
https://ncbi.nlm.nih.gov/pubmed/33449393
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/cam4.3710
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky